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1 Drug description 
Generic/Brand name/ATC code:  
Everolimus /Afinitor® or Votubia®/ L01XE10 or L04AA18 
Developer/Company:  
Novartis AG 
Description:  
Everolimus, is an orally active immunosuppressant analogue of sirolimus, a 
macrolide antibiotic produced by Streptomyces hygroscopicus [1]. It inhibits 
mTOR (mammalian target of rapamycin), a serine-threonine kinase acting 
as a signal transducing protein, which is a central regulator of tumour cell 
division and blood vessel growth in cancer cells and signals information via 
the regulation of multiple downstream pathways [2]. The inhibition of 
mTOR by everolimus has been shown to reduce cell proliferation, angio-
genesis, and glucose uptake in-vitro and/or in-vivo. In addition, everolimus 
inhibits the expression of hypoxia-inducible factor (e.g., HIF-l) and reduces 
the expression of vascular endothelial growth factor (VEGF) [3]. 
Exemestane is a third generation aromatase inhibitor (AI) for the hormonal 
treatment of oestrogen–receptor (ER)-dependent tumours. It irreversibly 
suppresses oestrogen production by inhibiting steroidal aromatase [1]. 
Afinitor® is available as 5 mg or 10 mg tablets, Votubia® as 2.5 mg, 5 mg and 
10 mg tablets. Everolimus (Afinitor®/Votubia®) is administered orally with a 
recommended dosage of 10 mg once per day [2, 4, 5]. 
The most common adverse events (AEs) associated with everolimus include 
stomatitis, infections, rash, fatigue, diarrhoea, oedema, abdominal pain, 
nausea, fever, asthenia, cough, headache and decreased appetite [2, 4, 5]. 
2 Indication 
Everolimus (Afinitor® or Votubia®) in combination with exemestane is indi-
cated for the treatment of postmenopausal women with ER-positive, HER2-
negative locally advanced or metastatic breast cancer (BC) who are refrac-
tory to letrozole or anastrozole.   
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3 Current regulatory status 
Following the positive opinion adopted by the Committee for Medicinal 
Products for Human Use in June 2012 [6], the European Medicines Agency 
(EMA) granted market authorization of Afinitor®  
 for the treatment of hormone receptor (HR)-positive, HER2-negative 
advanced BC, in combination with exemestane, in postmenopausal 
women without symptomatic visceral disease after recurrence or pro-
gression following a non-steroidal aromatase inhibitor [2]. 
Beside this indication everolimus (Afinitor®/Votubia®) is also approved 
for the use in the European Union for the treatment of 
 patients with neuroendocrine tumours of pancreatic origin (unre-
sectable or metastatic, well- or moderately-differentiated neuroendo-
crine tumours of pancreatic origin in adults with progressive disease) 
[2]. 
 patients with renal cell carcinoma (advanced renal cell carcinoma, 
with progression on or after treatment with VEGF-targeted therapy) 
[2]. 
 patients with subependymal giant cell astrocytoma associated with 
tuberous sclerosis complex who require therapeutic intervention but 
are not amenable to surgery [5]. 
In July 2012, the U.S. Food and Drug Administration (FDA) approved ever-
olimus (Afinitor®) based on the results of a randomized, double-blind, mul-
ticenter trial:  
 for the treatment of postmenopausal women with advanced HR-
positive, HER2-negative breast cancer in combination with exeme-
stane, after failure of treatment with letrozole or anastrozole [7].  
In the U.S. market Afinitor® is furthermore licensed for the treatment of 
[4]: 
 advanced neuroendocrine tumours of pancreatic origin.  
 advanced renal cell carcinoma. 
 renal angiomyolipoma with tuberous sclerosis complex. 
 subependymal giant cell astrocytoma. 
4 Burden of disease 
Within the last 20 years, about 4,000 to 5,000 women were newly diagnosed 
with BC in Austria each year [8]. The mortality rate for BC was 1,500 in 
2009 [9]. Thus, with a percentage of 28.5%, BC is the most common type of 
cancer in females [10]. In the US, the median age at diagnosis of BC was 61 
years from 2005-2009 [11]. In Austria the majority of malignant neoplasms 
of the breast were diagnosed in women aged 55 to 74 years in 2007-2009 [8]. 
The age standardized (per 100,000 population, defined by WHO 2001) inci-
dence rate for BC in women increased from 66.4 in 1992 to a maximum of 
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77.8 in 2001 and dropped again to 69.4 in Austria in 2009. In the same pe-
riod, the age standardized death rate continuously declined from 24.7 (1992) 
to 17.3 (2009) [8].  
Several well-established factors have been associated with an increased risk 
of BC, including age, positive family history, nulliparity, early menarche, a 
personal history of BC and genetic factors [12]. 
The American Joint Committee on Cancer has designated a staging by Tu-
mour Node Metastasis (TNM) classification to define BC. The TNM pro-
vides a strategy for grouping patients with respect to prognosis. Besides the 
staging of the primary tumour, the extent to which regional lymph nodes are 
involved and the absence or presence of distant metastases are taken into ac-
count, leading to four main stage groupings (stage T1 to T4) where locally 
advanced BC is coded as stage III and metastatic BC as stage IV [13, 14]. In 
2007/2009, 23.9% of female patients in Austria with initially diagnosed BC 
had regional disease (spread to regional lymph nodes) and 5.2% had dis-
seminated disease [15]. In the US, the 2002-2008 overall 5-year relative sur-
vival rate was 83.9% for regional BC and 23.8% for metastatic BC [11]. Ac-
cording to Statistik Austria the 5-year relative survival for regional or metas-
tatic BC is 60% and 10%, respectively [16]. The median overall survival 
(OS) for women with metastatic BC approaches two years, with a range from 
a few months to many years [17], while the median survival for women with 
stage III disease is less than five years [18]. The above-mentioned survival 
data refer to locally advanced or metastatic BC irrespective of receptor status 
with a probably better prognosis associated with HR-positive, HER2-
negative state. 
Approximately 60% to 70% of all invasive BC are HR-positive at the time of 
diagnosis [19], resulting in about 2,400 – 3,500 women being diagnosed with 
HR-positive BC in Austria each year. Of these, about 90% are believed to be 
HER2-negative [1]. 
Advanced BC comprises metastatic BC (stage IV) and locally advanced BC 
(stage III) [20]. Prognostic factors for advanced disease include the length of 
the relapse-free interval after the initial treatment, the number of metasta-
ses, locations involved (worse prognosis with hepatic, lymphangitic pulmo-
nary metastases, carcinomatous meningitis) and biological markers (e.g., 
good prognosis is associated with HR-positive state). Additionally, weight 
loss, poor performance status and age less than 35 years in woman with early 
stage BC determine an unfavourable prognosis [17]. Biological markers for 
prognosis as well as for therapeutic decisions include oestrogen receptor, 
progesterone receptor and HER2-status [21].  
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5 Current treatment 
The choice of therapy for BC is based on a number of prognostic and predic-
tive factors like tumour histology, characteristics of the primary tumour, 
axillary node status, HR- and HER2-status, presence of detectable metas-
tatic disease, comorbid conditions, age, and menopausal status [22]. 
Advanced HR-positive, HER2-negative BC is best treated with a multimo-
dality therapy including the treatment of the local disease with surgery, ra-
diation therapy, or both, and the treatment of systemic disease with endo-
crine therapy, cytotoxic chemotherapy, biologic therapy or combinations of 
these. Neoadjuvant systemic therapy, in particular neoadjuvant chemother-
apy, has become the standard approach for patients with locally advanced, 
inoperable BC [23]. When making treatment choices there is a trade-off be-
tween quality-of-life (QoL), the risks of toxicity and the likelihood of benefit 
in terms of improving symptoms or survival [24].  
For metastatic BC the therapy is mainly palliative in intent and the treat-
ment should be tailored individually. Ultimately, the choice of therapy 
should be based on patient preferences. Clinical advice will take into ac-
count the presence or absence of comorbidities, prior treatment and treat-
ment effectiveness, performance status, the site and extent of disease, the 
presence or absence of symptoms, and the rate at which the disease appears 
to progress [24]. 
Treatment options for locally advanced and metastatic BC are: 
 endocrine therapy 
Hormonal therapies are widely used in the management of ad-
vanced BC and are appropriate for approximately 70% of patients 
[24]. The first-line endocrine treatment for premenopausal women 
with HR-positive advanced BC is tamoxifen, while AIs (e.g. ana-
strozole, letrozole) are contraindicated. AIs, rather than tamoxifen, 
are suggested as first-line endocrine treatment for postmenopausal 
women with HR-positive advanced BC [25]. Although HR-positive 
tumours are most likely to respond to endocrine therapy, it is 
known that not all patients who have HR expressing tumours re-
spond to endocrine manipulation (i.e. de novo resistance) and a 
substantial number of patients who do respond will develop disease 
progression or recurrence while on therapy (i.e. acquired resistance) 
[26]. On disease progression, other classes of AIs (e.g. exemestane) 
and the ER antagonists (e.g. fulvestrant, tamoxifen) are used as sec-
ond-line treatment options. Some studies suggest a relative resis-
tance of HER2-overexpressing tumours to endocrine therapy, which 
may be higher for ligand binding agents like tamoxifen and lower 
for ligand-depleting agents like AIs [27]. But as study results are 
conflicting, according to recommendations of an expert panel con-
vened by the American Society of Clinical Oncology (ASCO) HER2 
expression should not be used to make decisions regarding hor-
mone therapy in either the adjuvant or metastatic disease setting 
[28]. 
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 chemotherapy  
Chemotherapy is used for the treatment of both HR-positive and 
HR-negative patients with advanced BC [24]. Patients whose tu-
mours have progressed on hormone therapy or patients with vis-
ceral metastases are also candidates for chemotherapy [29]. A num-
ber of different chemotherapy drugs, or classes of drug, are used, 
including taxanes, capecitabine, vinorelbine, alkylating agents, 
platinum-based drugs and anthracyclines [24]. Whether single-
agent chemotherapy or combination chemotherapy is preferable for 
first-line treatment is unclear [29]. 
 local-regional treatment 
For patients with operable locally advanced BC the options for lo-
cal-regional treatment of the primary tumour include breast-
conserving surgery plus radiation therapy, mastectomy plus recon-
struction, and mastectomy alone. Surgical staging of the axilla 
should also be performed. Radiation therapy is regularly employed 
after breast-conservation surgery. Adjuvant radiation therapy can 
be indicated for postmastectomy patients. The main goal of adju-
vant radiation therapy is to eradicate residual disease thus reducing 
local recurrence [30].   
For patients with metastatic BC surgery may be indicated for se-
lected groups. Examples include patients who need mastectomies 
for fungating (marked by ulcerations and necrosis)/painful breast 
lesions, parenchymal brain or vertebral metastases with spinal cord 
compression or isolated lung metastases [29]. In patients with me-
tastatic BC radiation therapy has a major role in the palliation of 
localized symptomatic metastases. Indications include painful bone 
metastases, unresectable central nervous system metastases, bron-
chial obstruction, and fungating/painful breast or chest wall le-
sions. Radiation therapy is also used after surgery for decompres-
sion of intracranial or spinal cord metastases and following fixation 
of pathologic fractures [29]. For patients with bone metastases the 
use of bisphosphonates should also be considered to reduce skeletal 
morbidity [29].  
6 Evidence 
A systematic literature search for primary literature in medical databases 
(Medline/Pubmed, Embase, Cochrane Central Register of Controlled Trials) 
was conducted on 3rd August 2012 and yielded 130 records after removal of 
duplicates. Of those, 7 records reporting on one phase III trial were included 
[31-37]. In addition a hand search was performed which included reference 
lists of topic related reviews (retrieved from the Cochrane databases and 
CRD) and the websites of the EMA and the FDA. This search resulted in 3 
further publications belonging to the already identified RCT [38-40]. On re-
quest the manufacturer sent 5 additional conference posters relevant to the 
topic [41-45]. In summary 15 publications (2 full text publications, 1 letter 
and 12 conference abstracts) reporting on one relevant phase III trial (BO-
LERO-2) were identified [31-45]. 
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6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy 
Study title: Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women 
With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Le-
trozole or Anastrozole [32, 33, 35-42] 
Study  
identifier 
ClinicalTrial.gov: NCT00863655 
EudraCT: 2008-008698-69  
CRAD001Y2301 
Randomised (2:1 ratio), two-arm double-blind, multi-centre (189), international (24 
countries) study; N=724  
allocation randomly to 2 treatment groups (485 everolimus-exemestane group, 239 pla-
cebo-exemestane group); stratification (presence of visceral metastasis and previous 
sensitivity to endocrine therapy), ECOG performance status (0 - 2) and number of prior 
chemotherapy regimens for advanced disease (0 or 1); ITT analysis 
Design 
Duration  Enrolment: June 2009 to January 2011 
Ongoing (Expected completion date:  June 2014) 
Interim analysis (preplanned according to the protocol):  
11 February 2011 at 359 documented PFS events 
Median follow-up: 7.5 months 
Median duration of exposure in everolimus-exemestane group: 
      EVE 14.6 weeks, EXE 17.4 weeks 
Median duration of exposure in placebo-exemestane group: 
      Placebo 12.0 weeks, EXE 12.0 weeks 
Updated analysis 1:  
8 July 2011 at 457 documented PFS events 
Median follow-up: 12.5 months 
Updated analysis 2:  
15 December 2011 at 510 documented PFS events 
Median follow-up: 18 months 
Hypothesis Superiority of progression-free survival (PFS) 
Funding Novartis Pharmaceuticals 
Intervention Everolimus (EVE) + exemestane (EXE) 
EVE (10mg/day orally) and EXE (25mg/day orally).   
In case of adverse events two reductions in EVE dose (5mg/day, 5mg 
every other day) were allowed. Treatment was continued until dis-
ease progression, development of unacceptable toxicity or withdrawal 
of consent. 
Treatment groups 
Control Placebo + exemestane (EXE)  
Placebo (2 times a day orally) and EXE (25mg/day orally).   
Maintenance of treatment and allowed reductions in placebo dose like 
in the intervention group.  
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Progression-free 
survival 
(primary out-
come) 
PFS Defined as time from the date of randomization to the 
date of the first documented progression or death due to 
any cause.  
PFS as assessed by the local investigators on the basis of 
radiographic studies (every 6 weeks) was the primary out-
come. Patients without an event were treated as censored 
at the time of the last tumour assessment. In addition for a 
secondary supportive efficacy analyses a central assess-
ment by an independent radiology committee was done.  
For patients with measurable disease at baseline objective 
response and disease progression were determined using 
the Response Evaluation Criteria in Solid Tumors (RECIST 
version 2). In patients with bone only lesions (lytic or 
mixed) at baseline disease progression was determined in 
case of a new lytic lesion in bone, an unequivocal progres-
sion of an existing bone lesion, or a new lesion outside of 
bone. 
Patients who discontinued study treatment (except for 
progression) were required to follow the same schedule of 
assessments. 
Overall survival 
(key secondary 
endpoint) 
OS Defined as the time from date of randomization to date of 
death due to any cause. In case of unknown survival status 
OS data were censored at the date of last contact. 
Overall response 
rate 
(secondary end-
point) 
ORR Defined as the proportion of patients with best overall re-
sponse of complete response (CR) or partial response (PR). 
Clinical benefit 
rate  
(secondary end-
point) 
CBR Defined as the proportion of patients with either a best 
overall response of CR, PR or SD lasting for 24 weeks or 
longer. 
Deterioration of 
ECOG perform-
ance status 
(secondary end-
point) 
TTD-
ECOG-PS 
Time to definitive deterioration of ECOG performance 
status (0 fully active, pre-disease performance without re-
striction; 1 restricted in physically activity but able to work 
(light or sedentary nature); 2 all self-care but unable to 
work; 3 only limited self-care; 4 completely disabled; 5 
dead). 
Endpoints and 
definitions 
Quality of Life 
(secondary end-
point) 
TTD-QoL Time to definitive deterioration, defined as a 5% decrease 
in the global health status (GHS) score relative to baseline, 
with no subsequent increase above this threshold. For this 
evaluation the European Organization for Research and 
Treatment of Cancer quality of life core questionnaire 
(QLQ-C30) and the breast cancer module (QLQ-BR23) 
were used, with the subscale GHS as the predefined pri-
mary  QoL variable of interest. 
Horizon Scanning in Oncology 
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Results and analysis 
Analysis  
description 
Primary efficacy analysis:   
PFS based on radiologic studies assessed by local investigators for the everolimus-
exemestane group compared with the placebo-exemestane group. A log-rank test and a 
two-look Lan–DeMets group sequential design with an O’Brien–Fleming-type boundary 
at a one-sided cumulative 2.5% level of significance were used to detect a hazard ratio 
of 0.74 with 90% power.  
For the final analysis 528 PFS events (i.e. either progressed or died due to any cause) 
were required, which based on further assumptions resulted in 705 patients to be ran-
domized. The interim analysis was prespecified after the observation of 359 PFS events.  
All randomly assigned patients were included in the efficacy (ITT) analysis. 
Inclusion Postmenopausal women;   
ER-positive, HER2–negative advanced breast cancer;   
refractory to the NSAIs letrozole or anastrozole (defined as ei-
ther recurrence during adjuvant treatment / within 12 months 
after its completion or as progression during the most recent 
systemic therapy for advanced disease / within 1 month after its 
completion);   
at least one measurable lesion or lytic/mixed bone lesions 
Exclusion ECOG performance status of 3 or greater; more than one prior 
chemotherapy regimen for advanced disease; prior hormonal 
therapy with exemestane; prior mTOR inhibitor therapy;   
history of brain metastases  
Analysis  
population 
Characteristics 724 women with ER-positive, HER2-negative advanced BC (72% 
progesterone-receptor-positive) 
 
Control (n=239) vs. Intervention(n=485): 
Median age (years [range] ): 61 [28-90] vs. 62 [34-93]  
Ethnicity White/Asian/Black (%): 78/19/1 vs. 74/20/3  
ECOG performance status 0/1/2 (%): 59/35/3 vs. 60/36/2  
Disease-free interval: 
   median (months [range] ): 57 [5-316] vs. 58 [1-340]   
   <12 mo/12-24 mo/>24 mo (%):  4/6/54 vs. 2/5/56   
Measurable disease (%):  68 vs. 70  
Visceral disease (%):  56 vs. 56  
Metastases (%):   
   lung/liver/bone: 33/30/77 vs. 29/33/76   
   ≥ 3 metastatic sites :  37 vs. 36   
Previous endocrine therapy:  
   any antiestrogen (%):  59 vs. 57 
   letrozole or anastrozole (%):  100 vs. 100 
Previous sensitivity to endocrine therapy (%):  84 vs. 84  
Prior chemotherapy (%)  
   (neo-)adjuvant only/for metastatic disease:  40/26 vs. 44/26 
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Treatment group Control (Placebo + EXE) Intervention (EVE + EXE) 
Number of subjects 239 485 
PFS, locA (months) 
median 
95%CI 
[157 events] 
2.8 
2.8-4.1 
[202 events] 
6.9 
6.4-8.1 
PFS, centA (months) 
median 
95%CI 
[104 events] 
4.1 
2.8-5.8 
[114 events] 
10.6 
9.5-not reached 
ORR, locA (%) 
95% CI 
CR/PR/SD/PD/U 
0.4 
0.0-2.3 
0.0/0.4/58.6/31.4/9.6 
9.5 
7.0-12.4 
0.4/9.1/70.1/9.9/10.5 
ORR, centA (%) 
95% CI 
CR/PR/SD/PD/U 
0.4 
0.0-2.3 
0.0/0.4/64.4/21.8/13.4 
7.0 
4.9-9.7 
0.0/7.0/74.6/5.6/12.8 
OS (months) NR NR 
Deaths 31 (13.0%) 52 (10.7%) 
TTD-ECOG-PS NR NR 
Results 
(preplanned in-
terim analysis 
7.5 mo f/up  
[35, 36]) 
 TTD-QoL NR NR 
Comparison groups  Intervention vs Control 
HR 0.43 
95% CI 0.35-0.54 
PFS, locA 
P value  <0.001 
HR 0.36 
95% CI 0.27-0.47 
PFS, centA 
P value  <0.001 
Point estimate NR 
Variability NR 
ORR, locA 
P value  <0.001 
Point estimate NR 
Variability NR 
ORR, centA 
P value  <0.001 
Point estimate NR 
Variability NR 
OS 
P value  NR 
Point estimate NR 
Variability NR 
Deaths 
P value  NR 
TTD-ECOG-PS P value ns 
Effect estimate 
per comparison 
(interim analysis 
7.5 mo f/up 
[35, 36]) 
TTD-QoL P value ns 
Horizon Scanning in Oncology 
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Treatment group Control (Placebo + EXE) Intervention (EVE + EXE) 
Number of subjects 239 485 
PFS, locA (months) 
median 
 
3.2 
 
7.4 
PFS, centA (months) 
median 
 
4.1 
 
11.0 
ORR, locA (%) 1.3 12.0 
CBR (%) 25.5 50.5 
OS (months) NR NR 
Deaths 54 (22.6%) 84 (17.3%) 
Results 
(updated analysis 
12.5 mo f/up 
[37, 38]) 
TTD-QoL (months) NR NR 
Comparison groups  Intervention vs Control 
HR 0.44 
95% CI 0.36-0.53 
PFS, locA 
P value  <0.001 
HR 0.36 
95% CI 0.28-0.45 
PFS, centA 
P value  <0.001 
ORR, locA P value  <0.0001 
CBR P value  <0.0001 
OS P value  NR 
Deaths P value  NR 
Effect estimate 
per comparison 
(updated analysis 
12.5 mo f/up 
[37, 38]) 
TTD-QoL P value ns 
Treatment group Control (Placebo + EXE) Intervention (EVE + EXE) 
Number of subjects 239 485 
PFS, locA (months) 
median 
95%CI 
 
3.2 
2.8-4.1 
 
7.8 
6.9-8.5 
PFS, centA (months) 
median 
95%CI 
 
4.1 
2.9-5.6 
 
11.0 
9.7-15.0 
ORR, locA (%) 
95%CI 
1.7 
0.5-4.2 
12.6 
9.8-15.9 
CBR (%) 
95%CI 
26.4 
20.9-32.4 
51.3 
46.8-55.9 
OS (months) NR NR 
Deaths 77 (32.2%) 123 (25.4%) 
Results 
(updated analysis 
18 mo f/up 
[2, 41, 42]) 
TTD-QoL (months) 
median 
95%CI 
 
5.8 
4.2-7.2 
 
8.3 
7.0-9.7 
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Comparison groups  Intervention vs Control 
HR 0.45 
95% CI 0.38-0.54 
PFS, locA 
P value  <0.0001 
HR 0.38 
95% CI 0.31-0.48 
PFS, centA 
P value  <0.0001 
ORR, locA P value  <0.0001 
CBR P value  <0.0001 
HR 0.77 
95% CI 0.57-1.04 
OS 
P value ns 
Deaths P value  NR 
HR 0.74 
95%CI 0.58 - 0.95 
Effect estimate 
per comparison 
(updated analysis 
18 mo f/up 
[2, 41, 42]) 
TTD-QoL 
P value  sig 
BC … Breast cancer; CI … Confidence interval; CBR … Clinical benefit rate; centA … central assessment; 
CR … complete response; ECOG … Eastern Cooperative Oncology Group; ER … Estrogen-receptor; 
EVE … Everolimus; EXE … Exemestane; f/up … follow-up; GHS … Global health status; HER2 … Human 
epidermal growth factor receptor 2; HR … hazard ratio; ITT … Intent-to-treat; locA … local assessment; 
mTOR … mammalian target of rapamycin; mo … months; NR … Not reported; ns … not significant; 
NSAI … non steroidal aromatase inhibitor; ORR … Overall response rate; OS … Overall survival; 
PFS … Progression-free survival; PD … progressive disease; PR … partial response; QoL … Quality of Life; 
RECIST … Response Evaluation Criteria in Solid Tumors; SD … stable disease; sig … significant; TTD 
ECOG-PS … Time to definitive deterioration in ECOG performance status; TTD-QoL … Time to definitive 
deterioration in Quality of Life; U … unknown 
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Table 2: Most frequent adverse events (interim analysis at 7.5 months follow-up) [35, 36] 
Grade (according to 
NCI CTCAE version 
3.0) 
Outcome  Control  
(Placebo + EXE)
(N = 238) 
Intervention  
(EVE + EXE) 
(N = 482) 
All 12% 23% 
SAE 
attributed to study treatment 1% 11% 
Stomatitis 1% 8% 
Anaemia <1% 5% 
Dyspnoea 1% 4% 
Hyperglycaemia <1% 4% 
Fatigue 1% 3% 
Aspartate aminotransferase level increased 1% 3% 
Pneumonitis 0% 3% 
Alanine aminotransferase level increased 2% 3% 
Diarrhoea 1% 2% 
Thrombocytopenia 0% 2% 
Asthenia 0% 2% 
Rash 0% 1% 
Decreased appetite 0% 1% 
Cough 0% 1% 
Decreased weight 0% 1% 
Arthralgia 0% 1% 
Peripheral oedema <1% 1% 
Nausea 1% <1% 
Grade 3   
(only AEs≥1% in 
one arm) 
Back pain 1% 0% 
Anaemia <1% 1% Grade 4   
(only AEs≥1% in 
one arm) Thrombocytopenia <1% 1% 
All (n) 1 7  
sepsis (n) 0 2 
pneumonia (n) 1 1 
tumour haemorrhage (n) 0 1 
cerebrovascular incident (n) 0 1 
renal failure (n) 0 1 
Deaths attributed 
to SAEs 
suicide (n) 0 1 
AE … Adverse event; CTCAE … Common Terminology Criteria for Adverse Events; EVE … Everolimus; 
EXE … Exemestane; NCI … National Cancer Institute; Common Toxicity Criteria; SAE … Serious 
adverse event 
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In this international double-blind multi-centre trial [31-45], 724 postmeno-
pausal women with ER-positive and HER2-negative advanced BC refractory 
to previous nonsteroidal aromatase inhibitors (letrozole or anastrozole) re-
ceived exemestane either in combination with everolimus or with placebo. 
To be included, patients had to have an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0-2 and not more than one prior che-
motherapy for advanced disease. 485 women were randomly assigned to the 
intervention group treated orally with 10 mg everolimus (an mTOR inhibi-
tor) plus 25 mg exemestane (an oral steroidal aromatase inhibitor) per day, 
and 239 women were allocated to the control arm receiving 10 mg matching 
placebo instead of everolimus. At baseline the randomized groups were simi-
lar in terms of patient characteristics, tumour status and prior therapies. 
For the primary endpoint, the preplanned interim analysis conducted after 
359 documented PFS events showed a significantly longer PFS in the inter-
vention group as determined by the local investigators (everolimus-
exemestane group 6.9 months vs. placebo-exemestane group 2.8 months; HR 
0.43 (95% CI 0.35-0.54; p<0.001)). The supportive efficacy analysis based on 
a central assessment by an independent radiology committee produced a 
similar group difference in PFS (HR 0.36 (95% CI 0.27-0.47; p<0.001), al-
though the median PFS in both groups was longer (10.6 vs. 4.1 months) than 
in the investigator-determined analysis. This is because for the central as-
sessment data were censored on the date of the last valid radiologic assess-
ment, also leading to fewer PFS events (218) for the central analysis. Sub-
group analyses including patient characteristics as well as tumour parame-
ters and previous treatment showed consistent PFS results across all groups. 
The two update analyses based on 457 PFS events at a median follow-up of 
12.5 months and on 510 PFS events at 18 months follow-up showed quite 
similar PFS differences between the intervention group and control group 
(for details see table 1). 
Only preliminary results have been available for the key secondary end point 
OS at 18 months (HR = 0.77, 95%CI 0.57 - 1.04). The authors stated that in 
all analyses up to now OS results were immature, with a total of 83, 138 and 
200 deaths, respectively. Fewer deaths occurred in the intervention group 
(interim analysis 10.7% vs. 13.0%; updated analysis at 12.5 months 17.3% vs. 
22.6%; updated analysis at 18 months 25.4% vs. 32.2%), but information on 
the statistical significance of these results is missing. 
Detailed information on tumour response and progression was only avail-
able in the interim analysis with significantly more patients in the interven-
tion group having a complete or partial response (see table 1). In all 3 analy-
ses, the ORR was significantly better in favour of the intervention group (lo-
cal assessment at 7.5 months: 9.5% vs. 0.4%, p<0.001; at 12.5 months 12.0% 
vs. 1.3%, p<0.0001; at 18 months 12.6% vs. 1.7%, p<0.0001). Also the re-
ported clinical benefit rates were significantly better in the intervention 
group (about 51% vs. about 26%, p<0.0001 at 12.5 months and 18 months 
follow-up, respectively). Further predefined efficacy outcomes were not re-
ported in detail. Based on the global health status (GHS, the primary QoL 
variable of interest) the analysis of the TTD in QoL showed no significant 
group difference at 7.5 and 12.5 months follow-up but was statistically sig-
nificant in favour of the intervention group at 18 months (8.3 vs 5.8 months). 
The TTD in ECOG performance status was only reported for the 7.5 months 
interim analysis with no difference between the groups. 
study population and 
inclusion criteria 
treatment group: 
everolimus + 
exemestane 
control group: placebo 
+ exemestane 
significantly longer PFS 
 
 
 
 
 
 
consistent across all 
subgroups 
similar PFS results in 
updated analysis 
data on OS yet 
immature 
 
fewer deaths 
ORR significantly better 
 
 
 
 
 
QoL differs depending 
on the time of analysis  
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More patients in the everolimus-exemestane group had serious adverse 
events (SAEs) compared to the placebo-exemestane group (interim analysis 
23% vs. 12%; updated analysis at 12.5 months 26.8% vs. 13.9%). Also a 
clearly higher proportion of SAEs was attributed to the study treatment in 
the intervention group (interim analysis 11% vs. 1%; updated analysis at 
12.5 months 11.2% vs. 1.7%) and more deaths were also related to study 
treatment in the intervention group (interim analysis: 1.4% (n=7) vs. 0.4% 
(n=1)) . 
In the intervention group, adverse events (AEs) were more often the reason, 
why patients discontinued their study treatment (8% vs. 3%) or particularly 
discontinued everolimus/placebo (19% vs. 4%). 
AEs of grade 3 or 4 affecting more than 1% of patients in at least one treat-
ment arm were stomatitis, anaemia, dyspnoea, hyperglycaemia, fatigue, 
pneumonitis, increased aspartate or alanine aminotransferase levels, diar-
rhoea, thrombocytopenia and asthenia. All of them occurred more often in 
the everolimus-exemestane group than in the placebo-exemestane group (for 
details see table 2). The reported proportions of patients with AEs of grade 3 
or 4 in the updated analyses were quite similar. 
The study authors concluded that, at the moment, patients’ benefit in terms 
of survival is unknown, but results show a clinical benefit. However, adding 
everolimus to exemestane increased the toxicity of the treatment, which has 
to be weighed against the benefit. 
6.2 Efficacy and safety - further studies 
No phase II trials investigating the effect of everolimus in combination with 
exemestane for the treatment of postmenopausal women with HR-positive 
locally advanced or metastatic breast cancer were identified. 
7 Estimated costs 
The price for one package Afinitor® 10 mg containing 30 tablets and thus for 
one month of therapy is € 3,600 [46, 47]. According to the summary of prod-
uct characteristics (SPC) and the BOLERO-2 study protocol the recom-
mended dose is 10mg daily for advanced breast cancer. Since the BOLERO-
2 study is ongoing, final data on the median duration of treatment with ever-
olimus are still missing. At the 18 months analysis the median duration of 
exposure in the everolimus-exemestane group was 29.5 weeks. Based on 
these data the overall costs for the treatment with Afinitor® per patient 
would result in about € 25,000. One can expect the actual costs being even 
higher, because 16.7% of the patients were still on study treatment at the 
time of analysis. As everolimus is approved only as add-on therapy to ex-
emestane, these expenses occur in addition to the costs of the aromatase in-
hibitor. 
AEs reason for 
discontinuation of 
treatment 
 
more AEs when 
treatment included 
everolimus 
more SAEs 
no phase II trials  
monthly treatment 
costs € 3,600 
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8 Ongoing research 
Beside the ongoing BOLERO-2 trial, whose interim results are presented in 
this report, 2 additional ongoing phase III studies evaluating everolimus for 
the investigated indication and intervention were found on 
www.clinicaltrials.gov or on www.clinicaltrialsregister.eu: 
 NCT01626222 (EudraCT 2011-006111-62): 4Ever – A multi-centre, 
open-label, single-arm study evaluating the efficacy and safety, QoL 
and health resources utilization in postmenopausal women with 
HR-positive BC progressing following prior therapy with non-
steroidal aromatase inhibitors (NSAI) treated with the combination of 
everolimus and exemestane. The estimated study completion date is 
May 2014. 
 EurdaCT 2012-000073-23: An open-label, multi-centre, expanded ac-
cess study evaluating the safety of everolimus (RAD001) in combina-
tion with exemestane in postmenopausal women with estrogen recep-
tor positive locally advanced or metastatic BC that is refractory to 
NSAIs. The estimated study completion date is not reported. 
Furthermore 2 ongoing phase III trials currently investigate everolimus in 
combination with trastuzumab for locally advanced or metastatic HER2-
positive BC: 
 NCT00876395 (BOLERO-1): to confirm the value of adding ever-
olimus as first-line therapy to weekly paclitaxel and trastuzumab as 
treatment of HER2-overexpressing metastatic BC. The estimated 
study completion date is December 2013.  
 NCT01007942 (BOLERO-3): will assess the combination everolimus, 
vinorelbine, and trastuzumab compared to the combination vinorel-
bine and trastuzumab with respect to progressive-free survival and 
over survival in HER2-positive women with locally advanced or me-
tastatic BC who are resistant to trastuzumab and have been pre-
treated with a taxane for second/third-line therapy) The estimated 
study completion date is May 2013. 
Another trial investigates everolimus in combination with letrozole as first-
line therapy for advanced BC (EudraCT 2004-000849-38). 
No ongoing phase II trial was found for everolimus in combination with ex-
emestane. There are various phase II studies investigating everolimus in 
combination with other agents (e.g. trastuzumab, carboplatin, lapatinib) or 
as mono-therapy for the treatment of BC.  
In addition everolimus is under investigation in phase III and phase II trials 
for primary BC and other cancer types including prostate cancer, colorectal 
cancer, thyroid cancer or non-small cell lung cancer. 
2 further ongoing 
phase III trials for 
everolimus + 
exemestane 
2 ongoing phase III trials 
for everolimus + 
trastuzumab and 1 for 
everolimus + letrozole 
no ongoing phase II trial 
for everolimus + 
exemestane 
plenty phase III and 
phase II studies for 
other indications 
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9 Commentary  
In July 2012, based on the results of the BOLERO-2 trial, both FDA and 
EMA extended the approval of everolimus (Afinitor®) to the treatment of 
HR-positive, HER2-negative advanced BC, in combination with exemestane, 
in postmenopausal women after recurrence or progression following a non-
steroidal aromatase inhibitor as a new indication [2, 7]. 
This phase III trial compared everolimus in combination with exemestane 
versus placebo plus exemestane in postmenopausal women with ER-positive 
and HER2-negative advanced BC. As the study is expected to be completed 
in June 2014, only results from the preplanned interim analysis and some 
updated results have been published until now. PFS, as determined by the 
local investigators, was the primary endpoint of this study. So far, analyses 
have shown a statistically significant absolute gain in PFS of 4 months for 
patients treated with everolimus. Supportive secondary analyses centrally 
assessed by an independent radiology committee but based on fewer events 
resulted in even longer PFS. Also, in all analyses the ORR was significantly 
higher in favour of the everolimus-exemestane group, almost all of these be-
ing partial responses. 
Overall AEs occurred more often in the everolimus group. This held also 
true for SAEs (23% vs. 12%) and AEs of grade 3 or 4 with clearly more pa-
tients in the intervention group suffering from stomatitis, anaemia, hyper-
glycaemia, dyspnoea, and pneumonitis. Consequently AEs leading to a dis-
continuation of the whole study treatment were more frequent in this group 
(8% vs. 3%). These proportions were even higher when it comes to the dis-
continuation of everolimus or placebo alone (19% vs. 4%). 
Despite the results of the BOLERO-2 trial some issues on everolimus as a 
treatment option for postmenopausal women with locally advanced or me-
tastatic BC still remain unanswered. For instance, although fewer deaths 
were noted in the intervention group, information regarding the statistical 
significance is missing. Because data on OS was immature, the final analysis 
has to show whether longer PFS and fewer deaths in the everolimus group 
still translate into a statistically beneficial OS. Moreover, improving QoL is 
an important aim for any therapy of advanced BC. In the BOLERO-2 trial, 
QoL results were different depending on the time of analysis. Only for the 
18 months follow-up recently published in a conference poster [41] a statis-
tically significant benefit for everolimus was shown. As results are inconsis-
tent, the final analysis has to proof the potential benefit. 
In addition, BOLERO-2 does not address the question on safety and efficacy 
of everolimus alone in comparison to everolimus in combination with aro-
matase inhibitors or in comparison to chemotherapy, the preferred regimen 
for women with more aggressive tumours (i.e. with symptomatic visceral 
disease). The EMA has therefore, and in contrast to the FDA, restricted the 
indication to patients without visceral involvement. Furthermore, efficacy of 
everolimus in HER2-positive BC has not been evaluated yet, but is currently 
being tested in two phase III trials (BOLERO-1, BOLERO-3).  
approved for treatment 
of HR-positive advanced 
BC since July 2012  
PFS increase by about 4 
months in HR-positive 
HER2-negative 
postmenopausal women 
more AEs in the 
everolimus group, most 
common stomatitis, 
anaemia, 
hyperglycaemia, 
dyspnoea, and 
pneumonitis 
questions still remaining 
to be answered: 
no published results on 
OS yet,  
QoL unclear 
everolimus 
monotherapy 
appropriate 
comparators 
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Due to the post marketing commitments between the manufacturer and the 
FDA answers to some of these questions can be expected in the near future 
[7]. These include submission of final OS results to the authorities by June 
2015 at the latest, but also the undertaking of a further RCT that will com-
pare everolimus in combination with exemestane versus everolimus alone 
versus capecitabine in women with ER-positive metastatic BC after recur-
rence or progression on letrozole or anastrozole (BOLERO-6). The comple-
tion of this study is scheduled for August 2016. 
In summary, the interim results of the BOLERO-2 study indicate that ever-
olimus in combination with exemestane can extend PFS when compared to 
exemestane alone. Overall, fewer women died in the everolimus group al-
though there was a higher rate of adverse events, serious adverse events and 
on-treatment deaths. Final data on QoL and the OS can be expected in 2015. 
These as well as the results of the upcoming BOLERO-6 trial will be helpful 
in deciding on the use of everolimus for the therapy in postmenopausal 
women with ER-positive, HER2-negative locally advanced or metastatic BC. 
 
post marketing 
commitments: 
final results 
further 3-arm RCT 
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